Mucosal Delivery Strategies for Cancer Vaccines

癌症疫苗的粘膜递送策略

• 批准号: 7371119
• 负责人: David Zaharoff
• 金额: $ 5.09万
• 依托单位: NATIONAL CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7371119
• 关键词: Antigens; Antitumor Response; Autoantigens; Cancer Model; Cancer Vaccines; Cells; Cervical; Classification; Colorectal; Colorectal Cancer; Development; Diffuse; Disease; Distant; Engineering; Experimental Models; Fostering; Goals; Immune; Immune response; Immune system; Immunity; Immunotherapy; In Vitro; Infection; Lead; Lung; Lymphoid; Lymphoid Tissue; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Metastatic Neoplasm to the Lung; Modeling; Mucosal Immune Responses; Mucosal Immunity; Mucous Membrane; Mus; Oral; Pathology; Research; Route; Site; Standards of Weights and Measures; Subcutaneous Injections; Surface; System; Testing; Tissues; Treatment Efficacy; Tumor Burden; Vaccination; Vaccines; immunogenic; improved; mucosal vaccination; mucosal vaccine; novel; pathogen; response; subcutaneous; tumor; vaccine delivery

The goal of this research is to develop novel mucosal vaccination platforms to improve the efficacy of therapeutic cancer vaccines. While recent research has demonstrated limited antitumor responses resulting from standard subcutaneous injections of cancer vaccines, antitumor efficacy may be substantially improved if vaccine delivery is site-specific and/or targeted directly to diseased tissues. Numerous cancers, e.g. lung, colorectal, cervical and Gl cancers, arise in tissues served by the common mucosal immune system (CMIS). Activation of a mucosal immune response may lead to a greater effector function against such cancers. Also, since mucosal immunity confers systemic immunity, mucosal vaccination has the potential to reach all cancers. A systematic study and development of mucosal vaccination platforms may enhance the efficacy of therapeutic cancer vaccines. In this study, five platforms will be developed to target mucosal lymphoid tissues via oral, intranasal, intravaginal, intrarectal and intrapulmonary routes. In addition to the salient benefits of immunotherapy, tailored mucosal administrations of vaccines will foster a greater understanding of mucosal immunity potentially impacting prophylaxes of cancers as well as other infections or pathologies.

本研究的目标是开发新型粘膜疫苗接种平台，以提高疫苗接种的功效 治疗性癌症疫苗。虽然最近的研究表明抗肿瘤反应有限 与标准皮下注射癌症疫苗相比，抗肿瘤功效可能会大幅提高 如果疫苗递送是针对特定部位和/或直接针对患病组织的。许多癌症，例如癌症肺， 结直肠癌、宫颈癌和胃肠道癌发生在由共同粘膜免疫系统(CMIS)服务的组织中。 粘膜免疫反应的激活可能会导致针对此类癌症的更大效应功能。还， 由于粘膜免疫赋予全身免疫力，因此粘膜疫苗接种有可能覆盖所有人群 癌症。粘膜疫苗接种平台的系统研究和开发可能会提高疫苗接种的功效 治疗性癌症疫苗。在这项研究中，将开发五个平台来靶向粘膜淋巴 通过口腔、鼻内、阴道内、直肠内和肺内途径进入组织。除了突出的 免疫疗法的好处，定制的粘膜疫苗给药将促进更好的理解 粘膜免疫可能影响癌症以及其他感染或病理的预防。